- Expertise. Mayo Clinic specializes in treating people with difficult cases of C. difficile who haven't responded to standard medical treatments or who have developed complications such as an inflamed colon.
Cutting-edge medicine. Mayo Clinic uses the polymerase chain reaction (PCR) test to confirm C. difficile infection, the most accurate diagnostic test available. The high sensitivity of PCR, together with its rapid turnaround time, allows prompt treatment for people with C. difficile infection, likely reducing opportunity for spreading infection and improving outcomes.
A new and emerging treatment for recurrent or stubborn C. difficile infections, the fecal microbiota transplant (FMT), has been performed at Mayo Clinic with a success rate higher than 90 percent. FMT therapy involves infusing healthy donor stools in people with C. difficile infections. Mayo Clinic performs extensive testing of donors and recipients before performing the procedure and offers the choice of related (family) or standard donors. Because donor testing typically isn't covered by insurance, Mayo Clinic has a standard donor pool to help reduce the cost to potential recipients.
- Team approach. Doctors who specialize in digestive and infectious diseases work closely with laboratory medicine and scientists specializing in the gut microbiome and individualized medicine to diagnose and treat your condition.
- Research. The Division of Gastroenterology and Hepatology at Mayo Clinic in Rochester, Minn., has opened a clinic especially dedicated to researching and treating C. difficile infection, including studies of the gut microflora and new therapies for C. difficile infection.
Mayo Clinic in Rochester, Minn., ranks No. 1 for digestive disorders in the U.S. News & World Report Best Hospitals rankings. Mayo Clinic in Scottsdale, Ariz., and Mayo Clinic in Jacksonville, Fla., are ranked high performing for digestive disorders by U.S. News & World Report.
Mayo Clinic: Answers you can trust
At Mayo Clinic, we assemble a team of specialists who take the time to listen and thoroughly understand your health issues and concerns. We tailor the care you receive to your personal health care needs. You can trust our specialists to collaborate and offer you the best possible outcomes, safety and service.
Mayo Clinic is a not-for-profit medical institution that reinvests all earnings into improving medical practice, research and education. We're constantly involved in innovation and medical research, finding solutions to improve your care and quality of life. Your doctor or someone on your medical team is likely involved in research related to your condition.
Our patients tell us that the quality of their interactions, our attention to detail and the efficiency of their visits mean health care — and trusted answers — like they've never experienced.
Why Choose Mayo Clinic
What Sets Mayo Clinic Apart
Jul. 16, 2013
- Khanna S, et al. Clostridium difficile infection: New insights into treatment. Mayo Clinic Proceedings. 2012;87:1106.
- Rebmann T, et al. Preventing Clostridium difficile infections: An executive summary of the Association for Professionals in Infection Control and Epidemiology's elimination guide. American Journal of Infection Control. 2011;39:239.
- LaMont JT. Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology. http://www.uptodate.com/home. Accessed March 25, 2013.
- Kelly CP, et al. Clostridium difficile in adults: Treatment. http://www.uptodate.com/home. Accessed March 25, 2013.
- Frequently asked questions about Clostridium difficile for healthcare providers. Centers for Disease Control and Prevention. http://www.cdc.gov/HAI/organisms/cdiff/Cdiff_faqs_HCP.html. Accessed March 25, 2013.
- Headley CM. Deadly diarrhea: Clostridium difficile infection. Nephrology Nursing Journal. 2012;30:459.
- LaMont JT. Clostridium difficile in adults: Clinical manifestations and diagnosis. http://www.uptodate.com/home. Accessed March 25, 2013.
- Surawicz CM, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. The American Journal of Gastroenterology. In press. Accessed March 25, 2013.
- Armstrong GD, et al. A potential new tool for managing Clostridium difficile infection. The Journal of Infectious Diseases. In press. Accessed March 25, 2013.
- Venugopal AA, et al. Current state of Clostridium difficile treatment options. Clinical Infectious Diseases. 2012;55:S71.
- Vancomycin hydrochloride. Micromedex Healthcare Series. http://www.micromedex.com. Accessed March 27, 2013.
- Fidaxomicin. Micromedex Healthcare Series. http://www.micromedex.com. Accessed March 27, 2013.
- Van Nood E, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. New England Journal of Medicine. 2013;368:407.
- Diarrhea. National Digestive Diseases Information Clearinghouse. http://digestive.niddk.nih.gov/ddiseases/pubs/diarrhea/#treated. Accessed March 27, 2013.
- Clostridium difficile and C. difficile toxin testing. Lab Tests Online. http://labtestsonline.org/understanding/analytes/cdiff/tab/test. Accessed April 15, 2013.
- Public workshop: Fecal microbiota for transplantation. U.S. Food and Drug Administration. http://www.fda.gov/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/ucm341643.htm. Accessed April 15, 2013.
- Steckelberg JM (expert opinion). Mayo Clinic, Rochester, Minn. April 16, 2013.
- Khanna S, et al. The epidemiology of community-acquired Clostridium difficile infection: A population-based study. The American Journal of Gastroenterology. 2012;107: 89.
- Khanna S (expert opinion). Mayo Clinic, Rochester, Minn. April 17, 2013.